HIV Remission Breakthrough: Antibody Hope

In a groundbreaking development that could transform the lives of millions worldwide, researchers have reported significant progress toward achieving lasting remission for HIV using engineered antibodies. This breakthrough, based on results from two major clinical trials, suggests that a “functional cure” for HIV may finally be within reach.

The Promise of Broadly Neutralizing Antibodies

The new approach leverages broadly neutralizing antibodies (bNAbs) – specialized proteins that can recognize and neutralize a wide range of HIV strains. Unlike traditional antiretroviral therapy (ART), which requires daily medication to suppress the virus, bNAbs offer the potential for long-term viral suppression with far less frequent dosing.

These engineered antibodies work by targeting specific parts of the HIV virus that remain relatively unchanged across different strains, making them particularly effective at combating the virus’s notorious ability to mutate and evade treatment. As researchers explain, bNAbs may also activate other immune cells to help destroy HIV-infected cells, potentially enhancing the body’s natural defenses against the virus.

HIV has long been a master of disguise, rapidly evolving after infection so that the body can’t produce new antibodies quickly enough to recognize and neutralize it. Some HIV even hides out in cells in an inactive state, invisible to the immune system. These evasion tactics have outwitted countless cure attempts over the decades.

Landmark Clinical Trials: FRESH and RIO

The progress is based on results from two independent clinical trials – FRESH and RIO – that have shown remarkable outcomes in achieving HIV remission without continuous medication.

The FRESH Trial

The FRESH (Future Response to Early Suppressive HAART) trial was led by renowned virologist Thumbi Ndung’u of the University of KwaZulu-Natal and the Africa Health Research Institute in South Africa. This trial focused on individuals who began ART treatment during early infection and were subsequently given infusions of broadly neutralizing antibodies.

In a significant finding, four out of twenty participants in the FRESH trial maintained undetectable viral loads for a median of 1.5 years without taking antiretrovirals. This suggests that the antibody treatment was able to work in conjunction with the immune system to keep the virus in check without daily medication.

The RIO Trial

The RIO trial, led by Professor Sarah Fidler from Imperial College London, showed similarly encouraging results. Set in the United Kingdom and Denmark, this trial demonstrated that six of 34 HIV-positive participants have maintained viral control for at least two years after stopping ART.

Presenting findings at the Conference on Retroviruses and Opportunistic Infections (CROI) 2025, Fidler highlighted how new antibody therapies could offer an alternative to current lifelong treatment regimens. “I do think that this kind of treatment has the opportunity to really shift the dial,” Fidler says, “because they are long-acting drugs” — with effects that can persist even after they’re no longer in the body. “So far, we haven’t seen anything that works like that.”

Leading Researchers and Institutions

This breakthrough represents the collaborative effort of leading scientists and premier research institutions worldwide:

Thumbi Ndung’u – Virologist at the University of KwaZulu-Natal and the Africa Health Research Institute in South Africa
Sarah Fidler – Professor at Imperial College London
Institutions – University of KwaZulu-Natal, Africa Health Research Institute, and Imperial College London

The international collaboration between these institutions, particularly with research centers in South Africa where HIV prevalence remains high, underscores the global commitment to finding effective treatments for this persistent pandemic.

Global Significance and Public Interest

With approximately 40 million people living with HIV worldwide, this breakthrough addresses one of the most pressing global health challenges of our time. The implications are profound – moving from lifelong daily medication to potentially intermittent or no treatment could dramatically improve quality of life for millions of people.

People with HIV can live long, healthy lives if they take antiretrovirals. But their lifespans are still generally shorter than those of people without the virus. And for many, daily pills or even the newer, bimonthly injections present significant financial, practical and social challenges, including stigma. For the last 15 to 20 years, there’s been a real push to ask, “How can we do better?”

The research has generated significant public interest, as evidenced by strong engagement in scientific communities and online forums. This level of attention reflects both the scientific community’s recognition of the breakthrough’s importance and the public’s hope for more manageable treatment options.

The dream, according to researchers, is what people call “curing HIV, or a remission in HIV.” While complete eradication remains challenging, these trials show that functional remission is becoming increasingly possible.

Looking Forward

While these results represent a significant step forward, researchers emphasize that larger trials and longer follow-up periods are needed to fully understand the potential and limitations of this approach. Questions remain about optimal dosing schedules, long-term safety, and effectiveness across diverse populations.

These landmark proof-of-concept trials show that the immune system can be harnessed to fight HIV. Researchers are now looking to conduct larger, more representative trials to see whether antibodies can be optimized to work for more people.

However, the possibility of achieving HIV remission without daily medication marks a paradigm shift in treatment approaches. For the millions of people living with HIV, this research offers hope that one day they may no longer need to take daily pills to stay healthy.

As the NIAID Director has noted, HIV remission free of antiretroviral therapy is becoming a feasible goal, with promising interventions including broadly neutralizing HIV antibodies leading the way. The World Health Organization continues to track these developments as part of its broader HIV/AIDS response strategy.